Trial Profile
Insulin sensitisation as a novel mechanism to lessen ischaemic burden in overweight non-diabetic patients with chronic stable angina: a pilot study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 18 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Nov 2005 New trial record.